Ajouter à une liste

Instrument Inactif

Communiqués Ophthalix Inc Other OTC

Actions

US6837362010

Recherche biotechnologique et médicale

Communiqués

25/03/21	Wize Pharma : to change name to Mawson Infrastructure Group Inc	AQ
23/03/21	MAWSON INFRASTRUCTURE GROUP INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
10/03/21	WIZE PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Changes in Control or Registrant, Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
01/03/21	WIZE PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
21/02/21	Vertua Limited (NSX:VERA) Cosmos Investment Impact	AQ
16/02/21	WIZE PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
04/02/21	WIZE PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
19/01/21	WIZE PHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
05/01/21	WIZE PHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/01/21	Wize Pharma : Receives Bonus BioGroup Shares from Escrow and Additional Bonus BioGroup Shares Totaling $1.3 Million	PR
31/12/20	WIZE PHARMA, INC. : Material Modification to Rights of Security Holders (form 8-K)	AQ
31/12/20	WIZE PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
30/12/20	Wize Pharma : and Cosmos Capital enter into Bid Implementation Agreement	PR
09/12/20	WIZE PHARMA, INC. : Unregistered Sale of Equity Securities (form 8-K)	AQ
30/11/20	WIZE PHARMA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
16/11/20	WIZE PHARMA : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
12/11/20	Wize Pharma : Announces Positive Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Tous les transcripts sur plus de 9000 sociétés, le jour de leur publication !

Débloquez-les Maintenant !

Débloquez-les Maintenant !

×